Delcath Systems Provides Update on Corporate Developments

View printer-friendly version

Data Release from Phase III Metastatic Melanoma Trial Still Expected in April

FDA Submission Timeline Remains on Schedule

NEW YORK, March 12 -- Delcath Systems, Inc. (Nasdaq: DCTH), which is testing its proprietary treatment system for primary and metastatic cancers to the liver, today provided an update on recent corporate developments.

Recent Highlights

  • Reached sufficient number of events in the Company's Phase III metastatic melanoma trial to allow initiation of data analysis, which is expected to be completed in April;
  • During the recent pre-NDA meeting with the FDA, and pursuant to the Company's Fast Track Status, the FDA confirmed the rolling submission filing strategy;
  • Signed the first research, distribution, sales and marketing agreement for the Delcath PHP Systemâ„¢ with Chi-Fu Trading Co., Ltd. in Taiwan;
  • Allowed by the FDA to initiate an Expanded Use Protocol for patients with ocular and cutaneous melanoma metastatic to the liver;
  • Initiated expansion of the Company's Scientific Advisory Board with the appointment of Professor Riccardo Lencioni, founder of the International Liver Cancer Association;
  • Significantly strengthened financial position via $32.6 million offering;
  • Cash and cash equivalents at February 26, 2010 was approximately $32.5 million;
  • The Company sponsored a Symposium on the Delcath PHP System during the Society of Surgical Oncology annual meeting in St. Louis, MO, March 3-7, 2010;
  • Delcath's PHP System is scheduled to be included in the following presentations in March and April:
    • The Seventh International Symposium on Melanoma and Other Cutaneous Malignancies, New York, New York, March 12-13;
    • The Society of Interventional Radiology 35th Annual Scientific Meeting, Tampa, Florida, March 13-18;
    • The 9th World Congress of the International Hepato-Pancreato-Biliary Association, Buenos Aires, Argentina, April 18-22; and
    • The Second European Conference on Interventional Oncology, Florence, Italy, April 21-24;
    • The AmSECT 48th International Conference, Reno, NV, April 28-May 1


"Since mid-November, our team has focused on executing our strategies to gain regulatory approval to market the Delcath PHP System both in the U.S. and in Europe, expand the potential benefits of the Delcath PHP System to patients worldwide and build increasing returns to our shareholders," said Eamonn P. Hobbs, President & CEO.  "Overall, we have made significant progress towards our goals and expect to begin the New Drug Application (NDA) process for FDA approval as soon as practically possible."

"The next operational milestone for our company is the April completion of data analysis from our Phase III trial," said Mr. Hobbs.  "The trial's data analysis involves the initial review by the principal clinical investigators at each enrolling center, an additional review by the Company's retained Clinical Research Organization, and a final review of medical images for verification of results conducted by an independent core lab before final statistical results are compiled by an independent biostatistical group.  We remain highly confident that the trial's data will meet the trial's primary endpoint, and our confidence was recently further buoyed by the FDA's acknowledgement of an expanded access program," added Mr. Hobbs. "Operationally, we are on track to have an inspectable Quality System at our Queensbury manufacturing facility by April, which is a key step in the positioning of the Company for commercialization."

"Our only recent adjustment to our plan has been a revision in our filing schedule to obtain CE Mark in Europe.  We recently confirmed that the Delcath PHP System will be treated as a Class III device in Europe, requiring additional validation testing and documentation. We anticipate filing for this approval by the end of the year, or approximately six months later than originally envisioned.  Once complete, these data will also be used to complete the CMC module of our rolling NDA submission in the U.S.  All other approval timelines are expected to remain on track," said Mr. Hobbs.

"We continue to actively negotiate strategic partnership transactions similar in structure to the agreement recently reached with Chi-Fu Trading Co. for the Taiwan market.  Our goal is to execute additional partnerships that will serve both strategic and financial needs. These partnerships will provide distribution and expanded clinical indications in key Asian markets as well as strengthen our capital position. Given that the timing of such agreements is unpredictable, we will continue to review other financing options to assure that the company maintains flexibility and is adequately capitalized to execute on the opportunities ahead of us as we move toward commercialization," concluded Mr. Hobbs.

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company is testing a proprietary, patented drug delivery system for the treatment of primary and metastatic liver cancers. Delcath's novel drug delivery platform is testing the delivery of ultra-high doses of anti-cancer agents to the liver while controlling the systemic exposure of those agents.  In addition to its fully enrolled Phase III metastatic melanoma study, the Company is currently conducting trials to treat other liver cancers. The Company maintains a broad intellectual property portfolio on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website at

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.


Delcath Systems, Inc.                                                   
Balance Sheets as of December 31, 2009 and 2008

December 31, December 31,
2009 2008
---- ----
Current assets
Cash and cash equivalents $35,486,319 $6,939,233
Investments - certificates of deposit - 3,847,904
Investments - treasury bills - 200,710
Prepaid expenses and other assets 799,416 353,346
------- -------
Total current assets 36,285,735 11,341,193
Property, plant and equipment
Furniture and fixtures 36,800 23,170
Computers and equipment 78,063 21,030
Leasehold improvements 431,425 -
------- ------
546,288 44,200
Less: accumulated depreciation (24,982) (26,711)
------- -------
Property, plant and equipment, net 521,306 17,489
------- ------
Total assets $36,807,041 $11,358,682
=========== ===========

Liabilities and Stockholders' Equity
Current liabilities
Accounts payable and accrued expenses $1,841,480 $703,489
Derivative instrument liability 11,207,214 448,318
---------- -------
Total current liabilities 13,048,694 1,151,807
---------- ---------

Commitments and contingencies - -

Stockholders' equity
Preferred stock, $.01 par value,
10,000,000 shares authorized; no shares
issued and outstanding - -
Common stock, $.01 par value; 70,000,000
shares authorized; 36,223,097 and
25,383,354 shares issued and 36,194,997
and 25,355,254 outstanding at December
31, 2009 and December 31, 2008,
respectively 362,231 253,834
Additional paid-in capital 92,835,174 57,343,507
Deficit accumulated during development
stage (69,371,755) (47,315,163)
Treasury stock, at cost: 28,100 shares at
December 31, 2009 and December 31, 2008 (51,103) (51,103)
Accumulated other comprehensive loss (16,200) (24,200)
------- -------
Total stockholders' equity 23,758,347 10,206,875
---------- ----------
Total liabilities and stockholders'
equity $36,807,041 $11,358,682
=========== ===========
Delcath Systems, Inc.
Income Statements as of December 31, 2009 and 2008

Quarter Quarter Year Year
ended ended ended ended
December December December December
31, 2009 31, 2008 31, 2009 31, 2008
-------- -------- -------- --------
Costs and expenses:

General and
expenses $1,771,374 $977,815 $3,898,705 $2,687,688
Research and
costs 3,653,658 1,645,345 9,637,050 5,378,335
--------- --------- --------- ---------
Total costs
and expenses 5,425,032 2,623,160 13,535,755 8,066,023
--------- --------- --------- ---------
loss (5,425,032) (2,623,160) (13,535,755) (8,066,023)
(expense) income (270,959) 296,335 (8,567,917) 1,103,682
Interest income 1,850 20,317 73,833 299,956
Other expense (3,441) (202,500) (26,753) (202,500)
Interest expense - - - -
--------- --------- --------- ---------
Net loss $(5,697,582) $(2,509,008) $(22,056,592) $(6,864,885)
=========== =========== ============ ===========
Common share data:
Basic and diluted
loss per share $(0.18) $(0.10) $(0.82) $(0.27)
====== ====== ====== ======
Weighted average
number of basic
and diluted
outstanding 31,040,910 25,346,756 27,072,556 25,300,703

Delcath Systems, Inc.                                                     
Statement of Cash Flows as of December 31, 2009 and 2008

2009 2008
---- ----
Cash flows from operating activities:
Net loss $(22,056,592) $(6,864,885)
Adjustments to reconcile net loss to net
cash used in operating activities:
Stock option compensation expense 1,578,673 379,546
Stock and warrant compensation expense 736,416 287,566
Depreciation expense 7,981 5,861
Amortization of organization costs - -
Loss on disposal of equipment 3,442 -
Derivative liability fair value adjustment 8,567,917 (1,103,682)
Changes in assets and liabilities:
Increase in prepaid expenses and other
assets (438,070) (5,894)
Increase (decrease) in accounts payable
and accrued expenses 1,137,991 578,211
--------- -------
Net cash used in operating activities (10,462,242) (6,723,277)
----------- ----------
Cash flows from investing activities:
Purchase of equipment or furniture and
fixtures (515,440) (8,313)
Proceeds from sale of equipment 200 -
Purchase of short-term investments - (200,710)
Purchase of marketable equity securities - (46,200)
Proceeds from maturities of short-term
investments 4,048,614 9,878,700
--------- ---------
Net cash provided by investing activities 3,533,374 9,623,477
Cash flows from financing activities:
Net proceeds from sale of stock and exercise
of stock options and warrants 35,475,954 -
Repurchases of common stock - -
Dividends paid on preferred stock - -
Proceeds from short-term borrowings - -
---------- ---------
Net cash provided by financing activities 35,475,954 -
---------- ---------
Increase in cash and cash equivalents 28,547,086 2,900,200
Cash and cash equivalents at beginning of
period 6,939,233 7,886,937
Cash and cash equivalents at end of period $35,486,319 $10,787,137
=========== ===========
Supplemental cash flow information:
Cash paid for interest $- $-
==== ====
Supplemental non-cash activities:
Cashless exercise of stock options $- $1,950
==== ======
Conversion of debt to common stock $- $-
==== ====
Common stock issued for preferred stock
dividends $- $-
==== ====
Conversion of preferred stock to common stock $- $-
==== ====
Common stock issued as compensation for
stock sale $- $-
==== ====
Fair value of warrants issued $2,190,979 $-
========== ====

This Site contains information and press releases about us. This information should be considered accurate only as of the date prepared. You acknowledge that this information may change over time and you should not assume that the information is accurate at a later date. Delcath Systems, Inc. is not obligated to update the press releases and information contained in this section of the Site.